The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LIXT | +5.34% | -91.27% | -38.57% | -93% |
| S&P | +13.95% | +78.35% | +12.25% | +354% |
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company. It engages in the business of utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in Pasadena, CA.
No news articles found for Lixte Biotechnology.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $22.94M | 445.5% |
| Market Cap / Employee | $11.47M | 0.0% |
| Employees | 2 | 0.0% |
| Net Income | -$1,980.40K | -100.8% |
| EBITDA | -$1,801.35K | -83.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.89M | 76.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -114.55% | 0.9% |
| Return On Invested Capital | -177.73% | -66.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$926.75K | 3.2% |
| Operating Free Cash Flow | -$926.75K | 3.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.14 | -1.02 | -1.04 | 21.29 | -734.57% |
| Price to Tangible Book Value | -2.14 | -1.02 | -1.04 | 21.29 | -734.57% |
| Enterprise Value to EBITDA | -11.45 | -7.22 | -2.03 | -15.68 | 154.12% |
| Return on Equity | -148.7% | -155.1% | -213.2% | -130.1% | 2.24% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
